Compare Recursion Pharmaceuticals Inc (RXRX) vs Upwork Inc (UPWK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Upwork Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.27 (market cap $1.81B), while Upwork Inc trades at $8.28 (market cap $1.04B). The key difference: Recursion Pharmaceuticals Inc is the larger of the two by market cap. Which is the better fit depends on your goals.
| RXRX | UPWK | |
|---|---|---|
Market Cap | $1.81B | $1.04B |
Sector | Health | Industrials |
52-Week High | $6.79 | $22.11 |
52-Week Low | $2.84 | $7.84 |
Enterprise Value | $1.33B | $806.15M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.33, up 1.22% in the last session, with a bearish technical signal and RSI near overbought levels. The company reported a Q2 2026 earnings miss with revenue of $54M and a net loss of $519M, reflecting a net margin of -961.97%. Recent news highlights participation in investor conferences and a Genentech partnership advancement, but competitive pressures and slow revenue growth remain concerns.
Outlook is cautious due to persistent losses and high cash burn, though partnerships provide some validation. Risks include execution challenges in drug discovery and reliance on milestone payments. Analysts show a mixed stance with 40% buy ratings, but the stock faces headwinds from weak profitability and bearish technical trends.
UPWK trades at $9.83, up 1.65% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 EPS of $0.41, beating expectations, but revenue guidance disappointed investors, causing a recent stock decline. Fundamentals show solid profitability with a 12.93% net income margin and attractive valuation ratios, including a P/E of 10.71. Cash flow from operations remains strong at $248.26 million for 2025.
The outlook is mixed: strong fundamentals and analyst buy ratings support upside potential, but weak guidance and active client declines pose near-term risks. Investment opportunity lies in valuation appeal and AI integration, balanced by execution challenges in a competitive freelance market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Upwork Inc
Upwork Inc is a United States-based company that operates an online marketplace that enables businesses to find and work with highly-skilled independent professionals. The develops platform for hiring and freelancing purposes. Its products offering include Upwork Basic, Upwork Plus, Upwork Business, Upwork Enterprise, and Upwork Payroll. The business generates revenue from Talent and Clients across the USA, India, the Philippines and the rest of the world. Substantial income is derived from providing services to Clients.
Read more on UPWK →
